leisure time -WSS

leisure time

author：explore 2025-08-11 11:46:09 - browse：67553

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： EMA weighs against approval for Mirati's lung cancer drug

WSS

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Humana CEO Bruce Broussard to step down in 2024

Humana CEO Bruce Broussard to step down in 2024

Life sciences deals on track to hit lowest point since 2017

hotspot

leisure time

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

Drug repurposing or repositioning? The language matters

What is artificial intelligence? Experts weigh in

Dobbs anniversary: the lost opportunity of abortion as health care

What is the Turing Test that determines if computers can think?

Duchenne breakthrough therapy leaves behind pioneering families

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Psychedelics group wrestles with new pharma identity

European regulators consider appeal over Amylyx ALS drug

explore

Nick Jonas talks about managing diabetes along with his career

How doctors and nurses shape Google's AI

Life sciences deals on track to hit lowest point since 2017

European regulators consider appeal over Amylyx ALS drug

Humana CEO Bruce Broussard to step down in 2024

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

focus

focus

focus

hotspot